NAMI SCC Website

 

 

 

 

 

 

 

Home
About
Links
Search
Advocacy
Editorial
Experiences
News
Newsletters
People
Research
Recovery
Santa Cruz
Site Map
Guest Book

 

 

Children's Mental Health Site of the Month

 

 

 

Schizophrenia Update

 

 

Schizophrenia Update

A Free Periodic Newsletter Covering the Latest news and Developments
Brought to you by http://www.schizophrenia.com
Series 2, Issue 7 - December 11th
, 2002
A Summary of Schizophrenia News and Events
Note: Please forward this newsletter to others who might benefit.
Back-issues of this newsletter are available at http://www.schizophrenia.com/newsletter/allnews/allnews.htm

E-mail Contact: szwebmaster@yahoo.com Subscriptions to Schizophrenia Update are free -- please forward this newsletter to others who may be interested. Visit http://www.schizophrenia.com to subscribe today! To unsubscribe, please see the link at the bottom of this newsletter.

horizontal rule

Schizophrenia.com Update

I apologize for the delay in getting this out - work and other activities have limited the time I can devote to www.schizophrenia.com. In fact, its becoming obvious that we need someone who can devote more time to the site if it is to reach its potential. So, I'm now officially looking for a new Executive Director (volunteer) for the schizophrenia.com non-profit organization. So far I've already had one person express interest - which is a good start - and I'm looking for more potential candidates, especially people who have some business management and/or non-profit organization management experience who can really drive things forward. Fund raising experience would be a definite plus. Top on our list of priorities will be finding additional funding sources - and to organize a User Committee to help guide in the development of the web site and in setting priorities.

If you, or someone you know, might be a good candidate for this position (Schizophrenia.com Executive Director) - please have them contact me at szwebmaster@yahoo.com)

Schizophrenia and Insulin? One other request... A researcher has asked me if I've if I've heard if anyone has anyone noticed beneficial or negative effects on their schizophrenic symptoms post insulin treatment. If you know of anyone (or a clinician who has treated someone in this situation) who has had both schizophrenia and diabetes - and been treated with insulin - and the insulin has seem to have had either negative or positive effects on the schizophrenic symptoms - please drop me an email and let me know.

Thanks,

Brian (szwebmaster@yahoo.com)

horizontal rule

Table of Contents
  1. Merck Research Head Steps Down to Focus on Treatments for Mental Illness
  2. Brain Imaging May Detect Schizophrenia in Early Stages
  3. 10 Keys to Recovery From Schizophrenia
  4. New Books on Schizophrenia
  5. Mental, neurological ills to draw US$5B Pfizer spending
  6. Is paternal age linked to schizophrenia risk in offspring?
  7. Cannabis link to mental illness strengthened
  8. Australia Scientists Identify Schizophrenia Genes
  9. Israeli Biotech: Schizophrenia Associated With the COMT Gene
  10. Gene Increases Schizophrenia Risk, Says Study
  11. Schizophrenia drugs linked to diabetes
  12. When Politics Is Personal - (Senator Pete V. Domnici and the shaping of the US Govt. policies on brain diseases/mental illness)
  13. LAURA'S LAW SIGNED BY GOVERNOR DAVIS NEW LAW REFORMS TREATMENT OF SERIOUSLY MENTALLY ILL
  14. UK law and upcoming injectable drugs to treat schizophrenia and bipolar disorder
  15. New Book: "Beyond Crazy" by Julia Nunes and Scott
  16. Path of doom starts with homelessness; Squalor 'breaks your heart'
  17. Research yields better meds; Reducing side-effects, psychotic episodes the goal

horizontal rule

Merck Research Chief Plans to Step Down to Pursue Treatments for Mental Illness

Edward Scolnick to Return to Labs, Seek Methods to Treat Mental Illness
By GEETA ANAND, THE WALL STREET JOURNAL

Merck & Co. said its head of drug research, Edward Scolnick, was stepping down after 17 years and plans to go back into the laboratories as a scientist pursuing treatments for mental illness, a personal crusade motivated by a family history of psychiatric disease.
 

horizontal rule

December 11, 2002
Brain Imaging May Detect Schizophrenia in Early Stages
By ERICA GOODE, New York Times

Scientists have known for some time that people who suffer from schizophrenia show abnormalities in the structure of their brains.

But in a new study, researchers for the first time have detected similar abnormalities in brain scans of people who were considered at high risk for schizophrenia or other psychotic illnesses but who did not yet have full-blown symptoms. Those abnormalities, the study found, became even more marked once the illness was diagnosed.

The subjects in the study who went on to develop psychoses had less gray matter in brain areas involved in attention and higher mental processes like planning, emotion and memory, the researchers found.

Experts said the study's results, reported yesterday in an online version of The Lancet, the medical journal, offered the possibility that imaging techniques might eventually be used to predict who will develop schizophrenia, a devastating illness that affects more than 2.8 million Americans. Doctors could then offer treatment while the disease was still in its earliest stages, possibly preventing further damage to the brain.

But Dr. Christos Pantelis, an associate professor of psychiatry at the University of Melbourne and the lead author of the report, cautioned that much more research was needed before magnetic resonance imaging, the method used in the study, could serve as a diagnostic tool for individual people with schizophrenia.

"I think it's still too early to say how helpful it will be," Dr. Pantelis said.

Still, other researchers called the study's findings exciting and said that the areas of the brain in which the abnormalities were found would now be an active focus for study.

"This is a terrific first step," said Dr. Paul Thompson, a professor of neurology at the University of California at Los Angeles and an expert on brain imaging and schizophrenia.

Dr. Herbert Y. Meltzer, a professor of psychiatry at Vanderbilt University and an expert on schizophrenia, said, "It proves that the psychosis is almost a late stage in the evolution of the disease process."

He added, "The key message is that this is a neurodevelopmental disorder and that changes in memory, learning, attention and executive decision-making precede the experience of the psychosis."

People who suffer from schizophrenia typically experience auditory hallucinations and have blunted emotional responses and difficulty with activities that require planning or other higher-level processes.

Some studies have suggested that the earlier the illness is treated with antipsychotic drugs the better the prognosis. At least two research groups, one led by Dr. Patrick McGorry, an author of the Lancet report, and another at Yale, are conducting studies in which young people who are experiencing some symptoms but have not yet developed schizophrenia are treated with antipsychotic drugs. But the studies have been controversial because it is not yet clear which symptoms predict later illness.

In the new study, the researchers used magnetic resonance imaging to scan the brains of 75 people who were deemed "at high risk" for psychosis because they had a strong family history of severe mental illness or had other risk factors, including transient or mild symptoms of mental disturbance or a decline in mental functioning.

Over the next 12 months, 23 of the subjects developed a full-blown psychosis and 52 did not fall ill, the researchers found.

A comparison of the brain scans from the two groups revealed significant differences in the volume of gray matter in areas of the frontal and temporal lobes and the cingulate gyrus. All three regions have been linked to schizophrenia by previous research, Dr. Pantelis said.

When the researchers conducted additional brain scans on some subjects who developed psychoses, they found further reductions in gray matter not seen in the scans taken before the illnesses were diagnosed.

 

 

===========================

From the University of California at Los Angeles:

10 Keys to Recovery From Schizophrenia

UCLA Neuropsychiatric Institute researchers have identified 10 key factors to recovery from schizophrenia. The findings open opportunities to develop new treatment and rehabilitation programs and to reshape the negative expectations of many doctors, patients and their families.

Based on analyses of the professional literature and the cases of 23 schizophrenia patients who successfully returned to work or school with their symptoms under control, the findings appear in the November 2002 edition of the International Review of Psychiatry.

Factors detailed in the study that influenced recovery included 1) family relationships, 2) substance abuse, 3) duration of untreated psychosis, 4) initial response to medication, 5) adherence to treatment, 6) supportive therapeutic relationships, 7) cognitive abilities, 8) social skills, 9) personal history and 10) access to care.

"Our findings join a growing body of research that flies in the face of the long-held notion that individuals diagnosed with schizophrenia are doomed to a life of disability with little expectation for productive involvement in society, a fatalistic view that in itself is damaging to prospects for recovery," said lead author Dr. Robert P. Liberman, a research scientist at the UCLA Neuropsychiatric Institute and professor of psychiatry at the David Geffen School of Medicine at UCLA.

"By understanding the dynamics of recovery, we can design more effective courses of treatment and combat the pessimism held by many doctors, patients and families struggling to cope with this debilitating disease," said Liberman, director of the UCLA Psychiatric Rehabilitation Program and Center for Research on Treatment and Rehabilitation of Psychosis. "Increasing the rate of recovery from schizophrenia will help destigmatize this disease, reduce the emotional burden on families, and lighten the financial weight on communities, states and the nation."

Liberman and his collaborator, Dr. Alex Kopelowicz, medical director of the San Fernando Mental Health Center and associate professor of psychiatry at UCLA, edited the November 2002 edition of the International Review of Psychiatry. Their articles are joined by those from an international array of investigators on the process of recovery, prospects for improving schizophrenia treatment and suggestions for future research.

Factors identified as keys to recovery from schizophrenia included:

1. Family relationships: Family stress is a powerful predictor of relapse, while family education and emotional support decrease the rate of relapse. Among study participants, 70 percent reported good or very good family relationships.

2. Substance abuse: National Institute of Mental Health research estimates the prevalence of lifetime substance abuse among schizophrenia patients at 47 percent, well above the overall rate. Though three-quarters of the study participants reported substance abuse prior to treatment, just 17.4 percent reported abuse after the onset of schizophrenia. None reported illicit drug use in the past year, and just two reported occasional alcohol consumption.

3. Duration of untreated psychosis: Longer duration of symptoms prior to treatment correlates directly with greater time to remission and a lesser degree of remission. Among study participants, only 13 percent reported a delay of more than a year between the onset of symptoms and treatment.

4. Initial response to medication: Improvement of symptoms within days of receiving antipsychotic drugs significantly predicts long-term results of treatment. Among the study group, 87 percent reported effective control of symptoms with their first antipsychotic medication.

5. Adherence to treatment: Failure to take antipsychotic medication as prescribed hampers both short-term and long-term recovery. All study participants reported adherence to psychiatric care and medication regimens.

6. Supportive therapy: Positive relationships with psychiatrists, therapists and/or treatment teams engender hope and are essential to improvement. Among study participants, 91 percent reported ongoing psychotherapy, and 78 percent reported that accessible and supportive psychiatrists and therapists contributed to their recovery.

7. Cognitive abilities: Neurocognitive factors such as working memory, sustained attention and efficient visual perception are strong predictors of recovery. Among study participants, all showed normal or near normal functioning on tests of flexibility in solving problems, verbal working memory and perceptual skills.

8. Social skills Negative symptoms, or poor interpersonal skills relative to social expectations, correlate with the degree of disability caused by schizophrenia. No study participants showed more than very mild negative symptoms.

9. Personal history: Premorbid factors, or those in place prior to the onset of the disease, that affect treatment outcome include education and IQ, age of onset, rapidity of onset, work history, and social skills. Among study participants, level of education was used as a measure of premorbid history. A total of 70 percent graduated from college before becoming ill, and an additional 13 percent completed two years of college. Three of the remaining four subjects worked full time before their illness began.

10. Access to care: Continuous, comprehensive, consumer-oriented and coordinated treatment is crucial to recovery. Among study participants, 91 percent reported receiving antipsychotic medication and psychotherapy, 47.8 percent social skills training, 56.5 percent family participation, 26 percent vocational rehabilitation, and 61 percent benefits from self-help groups.

The study:

Schizophrenia encompasses a group of psychotic disorders characterized by disturbances in thought, perception, emotion, behavior and communication that last longer than six months. In addition, the disorders are associated with disability in work, school, social relations and independent living skills. The cause or causes of schizophrenia is unknown. Genetic factors may play a role, as identical twins and other close relatives of a person with schizophrenia are more likely to develop the disorder. Psychological and social factors, such as drug abuse, stressful life challenges and interpersonal relationships, may also play a role in development.

In identifying factors to recovery, Liberman and his team reviewed a growing body of literature that show recovery from schizophrenia can occur under two conditions: 1) when the disorder is treated early with assertive case management and use of antipsychotic medication; and 2) when more chronic or relapsing forms are treated for lengthy periods of time with comprehensive, continuous care.

In addition, the researchers examined the cases of 23 schizophrenia patients who met specific recovery criteria, including remission of symptoms as well as successful functioning at work and school, independent living and social relationships.

The National Institute of Mental Health and the National Alliance for Research on Depression and Schizophrenia funded the study. UCLA Neuropsychiatric Institute researchers involved in the study with Liberman included Kopelowicz, Dr. Joseph Ventura and Dr. Daniel Gutkind.

The UCLA Neuropsychiatric Institute is an interdisciplinary research and education institute devoted to the understanding of complex human behavior, including the genetic, biological, behavioral and sociocultural underpinnings of normal behavior, and the causes and consequences of neuropsychiatric disorders. In addition to conducting fundamental research, the institute faculty seeks to develop effective treatments for neurological and psychiatric disorders, improve access to mental health services, and shape national health policy regarding neuropsychiatric disorders.
 

horizontal rule

(relatively) New Books on Schizophrenia:

October 4, 2002

No Sign Yet Of That Smoking Gun - Book Reviews By: Daniel Nettle

Note: Links below take you to the Amazon.com link for purchasing the book. The Amazon link also has 25 pages of sample reading from Nancy Andreasen's book for your review.

Brave New Brain: Conquering Mental Illness in the Era of the Genome By Nancy C. Andreasen Oxford University Press 368pp, Pounds 24.99 ISBN 0 19 514509 7

In Search of Madness: Schizophrenia and Neuroscience By R. Walter Heinrichs Oxford University Press 347pp, Pounds 32.50 ISBN 0 19 512219 4

Hardly a week goes by without our reading of a particular psychological disorder that has been traced to a rogue brain chemical, or brain area, or beyond that to a genetic variant. These two books, in their different ways, reflect the fact that psychiatric research today sits at the intersection of neuroscience and genetics, and a very long way from the psychodynamic terrain it once occupied. Nancy Andreasen is one of the ushers of this ongoing paradigm shift. Twenty years ago, one of her books, The Broken Brain, became the general reader's herald that the scientific consensus about psychological disorders was shifting. Here she returns to survey the ground, choosing this time the new genetics and brain scanning as the tools that are making light the dark recesses of the mind. Andreasen's book is a solid enough overview of some aspects of modern biological psychiatry. Her summaries of the techniques of contemporary human genetics, and of brain scanning and the cerebral architecture it reveals, are extremely clear and useful. By the time she comes to survey the main psychological disorders, though, she has run out of steam slightly. Thus, while these chapters constitute useful introductions to schizophrenia, affective disorders, anxiety and dementia for those who have no prior knowledge, there is little in the way of synthesis of what we now understand to be the nature of these disorders or of the puzzles that remain.

In the case of schizophrenia, for example, far from the twin searchlights of genetics and brain-scanning locating a nice clean smoking gun, they have revealed much more complexity and variability than we could possibly have imagined. Despite some welcome words about the need to avoid obstructive dichotomies (nature vs nurture, brain vs mind), Andreasen is not prepared to engage with the possibility that neurobiological research might make us question the whole conceptual framework - a set of neat, discontinuous disease categories - that her book employs. Anxiety and mood disorders, for example, are treated as separate chapters in the book without comment, while genetic and neurobiological evidence leads us increasingly to think of them as related or even different aspects of the same thing. Many of the brain abnormalities (and some of the genetic loci) associated with schizophrenia are also associated with bipolar mood disorders, a crossover difficult to accommodate within a discrete framework.

R. Walter Heinrichs's book takes us on a journey through the scientific literature on schizophrenia in search of the pathognomon. The fascinating thing about schizophrenia is not, as is sometimes alleged, that no physical basis has been found to the illness. On the contrary, physical differences between patient and control brains have been found in terms of overall size, size of various sub-parts, gray-matter thickness, neuronal density, neuronal orientation, size of cerebral ventricles, dopamine activity levels, density of D2 and D4 dopamine receptors, serotonin activity, glutamate... The list is almost endless. The problem is knowing which of these manifold differences is significant, especially since many of them have not proved consistent.

Heinrichs's methodology is so simple as to be beautiful, and produces wonderful clarity in a confusing field. He meta-analyses the literature on each of the pathognomic contenders. This is no mean feat since 2,000 research papers are published on schizophrenia each year. He concentrates not just on the statistical significance of differences, but on effect size, that is the magnitude of difference between patients and controls. For each abnormality, he comes up with a mean-effect size from the literature - a kind of balance sheet of the research world's findings.

The results are most illuminating. First, despite a lot of variability and non-replication, the balance of evidence shows that the brains (and behaviours) of schizophrenia sufferers do differ significantly from those of the rest of the population in multiple ways. Second, there is no single trait that is much more pathognomic than any other - no smoking gun. Third, the degree of difference is in no case very great. On many measures, schizophrenic brains differ from the rest of the population by about one standard deviation. This means that they are measurably different, but there is a range of variation in both patients and controls, and there is huge overlap between those who receive the diagnosis of schizophrenia and those who do not. Thus we have a huge amount of physical information that is all relatively poor at identifying the individuals with the disorder.

These are important results to have. The physical basis of schizophrenia is an area dogged by researchers narrowly pursuing their own favoured abnormality, be it dopamine receptors, glutamate or neuronal migration, without reference to other paradigms that are out there, and without an attempt to achieve an overall synthesis. The frequency of non-replication makes it difficult to know which results to rely on, and Heinrichs's method solves that problem. The work is pursued with great clarity and thoroughness. The only omission I noted was the failure to cover differences of asymmetry and lateralisation in the schizophrenic brain.

In short, the new techniques of genetics, brain-scanning and the like mean that we have no shortage of information about the basis of psychological disorders. Heinrichs in particular has given us a magisterial assessment of some of that evidence. The goal now must be to synthesise it into a more satisfactory conceptual framework.

Daniel Nettle is lecturer in biological psychology, Open University.
 

horizontal rule

National Post (f/k/a The Financial Post)
October 3, 2002 Thursday National Edition

Mental, neurological ills to draw US$5B Pfizer spending

GROTON, Conn. - Pfizer Inc. plans to spend about US$5-billion during the next five years to develop new treatments for neurological disorders and mental illness. A Pfizer spokesman said the pharmaceutical giant invested about US$1-billion, out of a total US$5.3-billion research and development budget, into these disorders in 2002. The company expects this commitment to continue for the next five years, making up the US$5-billion total. Pfizer's Neuroscience Research and Development Program is developing treatments for disorders such as depression and anxiety, epilepsy, Alzheimer's disease, schizophrenia, neuropathic pain and migraine.

horizontal rule

Is paternal age linked to schizophrenia risk in offspring?

Men who have a child in their advancing years may convey an increased risk of schizophrenia to their child, reveals a team from the US.

Even after accounting for maternal age and other confounding factors, the researchers found that for every 10-year increase in the age of the father at the birth of their child, the risk of that baby developing schizophrenia in adulthood increased by almost 1.5 times.

Alan Brown (New York State Psychiatric Institute, New York) and colleagues used data from the birth cohort of the Prenatal Determinants of Schizophrenia study to determine the relation of paternal age to schizophrenia or other schizophrenia spectrum disorders in 71 patients.

Analysis of paternal age as both a continuous and categorical variable revealed a monotonic increase in the rate of schizophrenia spectrum disorders with advancing paternal age categories.

Indeed, there was almost twice the rate of adult schizophrenia spectrum disorders in children of men who were 10 years older at the child's birth, irrespective of adjustment for maternal age, paternal education, paternal race/ethnicity, and parity.

When the risk of schizophrenia alone was assessed, paternal age showed a similar dose-related increase for risk as that found for schizophrenia spectrum disorders.

Discussing potential explanations for their findings in the American Journal of Psychiatry, the authors suggest a possible role of de novo mutations. These mutations, which accumulate with advancing paternal age, result from replication errors and defective DNA repair mechanisms that are thought to propagate in successive clones of spermatocytes.

"While further work is necessary to confirm this interpretation, our study nonetheless provides further evidence that advanced paternal age is a risk factor for schizophrenia spectrum disorders," the researchers report.

Am J Psychiatry 2002; 159: 1528–1533

horizontal rule

Cannabis link to mental illness strengthened
BBC News
23:01 21 November 02
Emma Young

The link between regular cannabis/marajuana use and later depression and schizophrenia has been significantly strengthened by three new studies.

The studies provide "little support" for an alternative explanation - that people with mental illnesses self-medicate with marijuana - according to Joseph Rey and Christopher Tennant of the University of Sydney, who have written an editorial on the papers in the British Medical Journal.

One of the key conclusions of the research is that people who start smoking cannabis as adolescents are at the greatest risk of later developing mental health problems. Another team calculates that eliminating cannabis use in the UK population could reduce cases of schizophrenia by 13 per cent.

Until now, say Rey and Tennant, there was "a dearth of reliable evidence" to support the idea that cannabis use could cause schizophrenia or depression. That lack of good evidence "has handicapped the development of rational public health policies," according to one of the research groups, led by George Patton at the Murdoch Children's Research Institute in Melbourne, Australia.

The works also highlights potential risks associated with using cannabis as a medicine to ease the symptoms of muscular sclerosis, for example.

Pharmacological effect

Patton's team followed over 1600 Australian school pupils aged 14 to 15 for seven years. Daily cannabis use was associated with a five-fold increased risk of depression at the age of 20. Weekly use was linked to a two-fold increase. The regular users were no more likely to have suffered from depression or anxiety at the start of the study.

The reason for the link is unclear. Social consequences of frequent cannabis use include educational failure and unemployment, which could increase the risk of depression. "However, because the risk seems confined largely to daily users, the question about a direct pharmacological effect remains," says Patton.

In separate research, a team led by Stanley Zammit at the University of Cardiff, UK, evaluated data on over 50,000 men who had been Swedish military conscripts in 1969 and1970. This group represents 97 per cent of men aged 18 to 20 in the population at that time.

The new analysis revealed a dose-dependant relationship between the frequency of cannabis use and schizophrenia. This held true in men with no psychotic symptoms before they started using cannabis, suggesting they were not self-medicating.

Genetic factors

Finally, researchers led by Terrie Moffitt at King's College London, UK, analysed comprehensive data on over 1000 people born in Dunedin, New Zealand in 1972 and 1973.

They found that people who used cannabis by age 15 were four times as likely to have a diagnosis of schizophreniform disorder (a milder version of schizophrenia) at age 26 than non-users.

But when the number of psychotic symptoms at age 11 was controlled for, this increased risk dropped to become non-significant. This suggests that people already at greater risk of later developing mental health problems are also more likely to smoke cannabis.

The total number of high quality studies on cannabis use and mental health disorders remains small, stress Rey and Tennant. And it is still not clear whether cannabis can cause these conditions in people not predisposed by genetic factors, for example, to develop them.

"The overall weight of evidence is that occasional use of cannabis has few harmful effects overall," Zammit's team writes. "Nevertheless, our results indicate a potentially serious risk to the mental health of people who use cannabis. Such risks need to be considered in the current move to liberalise and possibly legalise the use of cannabis in the UK and other countries."

Journal references: British Medical Journal (vol 325, p1195, p1199, p1212, p1183)
 

horizontal rule

Australia Scientists Identify Schizophrenia Genes
Tue Nov 26, 1:29 PM ET Add Health - Reuters to My Yahoo!
 

MELBOURNE (Reuters) - An Australian research team said on Tuesday it had identified 153 genes affected by schizophrenia in a step toward discovering the causes of the illness.

 

The 153 affected genes were identified after completing high-throughput screening of 12,000 genes in post-mortem studies of brain tissue from schizophrenia sufferers.

"Within that affected group will be the core genes that actually cause the symptoms of the illness, and clearly that is what we are trying to get at," Mental Health Research Institute Associate Professor Brian Dean told Reuters.

The research team at the institute's Rebecca Cooper Laboratories outlined its plans to identify the core genes to the Australian Health and Medical Research Congress.

"I think what is important about this is up until now schizophrenia is a psychiatric illness that is defined on symptoms alone," Dean said.

"What this gene screen has allowed us to do with our research into the future, is now base our research on genes that we now know are affected in brain tissue from someone with the illness."

Dean said general current thinking is that genetics plays a major role in the development of schizophrenia, but studies with the identical twins of sufferers suggest there must also be another factor that brings on the disease.

"They have got identical genetic material essentially, but the likelihood of them getting the illness is only actually 46%," he said.

"There has to be something else other than genes involved, but if we can get at the core genes, then we can start thinking about what the second hit might be that affects the susceptible individual."

The research has implications for improving treatment of the disease without some of the side effects of existing medication. The next stage involves more advanced screening of protein and genetic material, known as mRNA, to try and narrow down the number of genes that actually cause schizophrenia to possibly five or 10.

"The core of the problem rests in those genes," Dean said.

horizontal rule

Israeli Biotech: Schizophrenia Associated With the COMT Gene
IDgene Pharmaceuticals (Jerusalem) says it has discovered an association between the COMT (catechol-O-methyltransferase) gene and schizophrenia. The details of this finding will be published in next month's issue of The American Journal of Human Genetics and are now available online at www.journals.uchicago.edu/AJHG/home.html. "The genetic basis of schizophrenia is poorly understood and the data presented to date has been mostly inconclusive. IDgene has successfully produced the most statistically significant results ever reported in schizophrenia or in any other common polygenic disease. The study shows that the COMT gene may account for more than 20% of all schizophrenia patients. In the near future, we expect several additional discoveries of novel disease susceptibility genes, as well as genes responsible for variation in drug response," notes IDgene's CEO, Ariel Darvasi.

 

 

horizontal rule

University Of Toronto , 11/13/2002
 

Gene Increases Schizophrenia Risk, Says Study
Scientists at U of T have discovered the first "risk gene" for schizophrenia found in the general population.
 

An uncommon variation of a gene called Nogo, when inherited from both parents, increases the risk of developing schizophrenia, says a study to be published in Molecular Brain Research Nov. 15. Previous findings about other risk genes for the disease were restricted to specific ethnic groups.

"Finding a risk gene in the general population - the first finding of this type internationally - opens the door to discovering new and related risk genes. Now scientists will know where to look for related genes," says pharmacology and psychiatry professor Philip Seeman. "This will help in diagnosis and potentially in the design of new medications for treatment of this terrible disease," adds Seeman who worked on the study with psychiatry professor Teresa Tallerico, lead author and pharmacology graduate student Gabriela Novak and undergraduate student David Kim.

The study shows that one in five people with schizophrenia has this risk gene. Researchers found that 17 of 81 individuals with schizophrenia - 21 per cent - had inherited the uncommon Nogo variant gene from both parents. In a control group of individuals without schizophrenia, only three per cent had inherited the gene from both parents. People can inherit the variant Nogo gene from just one parent but there's a schizophrenia risk only when this gene is inherited from both parents. The gene does not suggest a diagnosis for schizophrenia but rather an increased predisposition to the illness.

One of the Nogo gene's functions is to produce proteins that inhibit the growth of nerve endings in the brain. Unlike the common form of Nogo, the variant gene has three extra chemical bases, known as CAA, in a region of the gene that regulates protein production. The researchers found that activity of the Nogo genes was higher in the post-mortem brain samples of individuals with schizophrenia. It is possible that these extra CAA bases lead the variant Nogo gene to produce more proteins, thereby reducing the number of nerve endings in regions of the brain associated with schizophrenia symptoms, Seeman says. However, more research is needed to confirm this.

"This study adds to the rapidly evolving theory that, in the brain of those who suffer from schizophrenia, the nervous system develops in a slightly altered fashion leading to the onset of symptoms such as hallucinations and delusions in young adulthood," says Seeman.

Although the cause of schizophrenia is not known, the treatment of the symptoms has been well-established since the 1970s. Antipsychotic medication is used to block the action of dopamine, an adrenaline-like chemical transmitter in the nervous system that becomes overactive in people with schizophrenia.

"This finding of a risk gene in the general population could lead to the development of medications outside the dopamine system, perhaps targeting the protein produced by the gene," suggests Seeman.

The study was supported by the National Alliance for Research on Schizophrenia and Depression, the Eli Lilly Research Fellowship in Women's Mental Health, the Stanley Foundation Scholars Mentors Program of the National Alliance for the Mentally Ill, the Canadian Institutes for Health Research, the Ontario Mental Health Foundation and the National Institute on Drug Abuse. Professor Tallerico is an Essel Investigator of the National Alliance for Research on Schizophrenia and Depression (NARSAD) and Professor Seeman is a Janice Lieber Investigator of NARSAD.

The University of Toronto, Canada's leading research university with 60,000 students, is celebrating its 175th anniversary in 2002.
 

horizontal rule

Schizophrenia drugs linked to diabetes
Last Updated Thu, 03 Oct 2002 15:11:37
HALIFAX - Some doctors are warning about a class of anti-psychotic drugs linked to life-threatening side effects.

Health Canada has received reports that Zyprexa is suspected as the cause of four diabetes-related deaths. The drug was approved for use in Canada in 1996 and is made by Eli Lilly.

Zyprexa is part of a new class of drugs called atypical anti-psychotics. A growing number of schizophrenics in the country are using the new drugs, such as Clozaril. There are 300,000 schizophrenics in Canada.

People with schizophrenia experience three major types of symptoms:
psychotic symptoms: delusions and hallucinations
deficit symptoms: diminished emotions, social withdrawal and low motivation
mood symptoms: depression to suicidal

"It helps me by calming me down because I'm also nervous, my legs shake and my hands tremble," says Richard Thompson of Edmonton who has gained more than 30 pounds (14 kg) and developed diabetes since taking the drugs. His doctors believe the drug is at least partly responsible for his weight gain.

The most common side effects associated with Zyprexa are:


drowsiness
insomnia
agitation
dizziness
Less common effects include skin rash, depression, fast heart rate and constipation
Other known, but less common, effects are listed as: skin rash, headache, depression, fast heart rate, constipation and weight gain.

Research published in the British Medical Journal and other journals suggest atypical anti-psychotics can cause diabetes.

"We suspect…those drugs interfere with some kind of chemical processes both in the brain and body and lead to the development of something called insulin resistance," says Dr. Pierre Chue, Thompson's doctor. "As that develops, the diabetes sets in."

Health Canada has received four reports of diabetes-related Zyprexa deaths over five years.

Two of those deaths involved teenage boys who fell into diabetic comas.

In the U.S., the government has collected reports of 140 people who developed diabetes after taking Clozaril.

The companies which make the drugs say people with schizophrenia tend to have unhealthy diets which put them at risk of getting diabetes.

Marie Josee-Poulin, a psychiatrist at Laval University in Quebec, says the evidence linking the drugs to diabetes isn't clear yet but she says the concerns are justified.

A Health Canada newsletter has warned doctors that atypical anti-psychotics may be associated with new cases of diabetes. Some doctors would like to see this as a clear warning on the label.

Both Poulin and Chue says too many doctors are unaware of the risks and side effects of the new class of anti-psychotics. They say patients should be closely monitored for signs of unstable blood sugars or weight gain.

Written by CBC News Online staff
 

bullet

horizontal rule

The New York Times, September 15, 2002

When Politics Is Personal - (Senator Pete V. Domenici and the shaping of the US Govt. policies on brain diseases/mental illness).

By Deborah Sontag; Deborah Sontag is a staff writer for the magazine.

'My daughter Clare, and it's spelled c-l-a-r-e, she's my fourth child of eight," Senator Pete V. Domenici began reluctantly, his voice soft and gravelly. "Clare was a beautiful, beautiful girl. Now she's all grown up, and she's, well, she's struggling. Struggle is a good word for it."

Domenici had been sitting beside me in an armchair in his Washington office, chatting about a re-election race that is causing him little anxiety. But when the conversation shifted to his family, and then specifically to his 40-year-old daughter, Clare, he rose abruptly and moved away, putting his solid senatorial desk between us. Sitting beneath a Navajo wall-hanging from his native New Mexico, he absorbed himself lining up pens on a yellow legal pad. A 70-year-old Republican, Domenici is not a soul-bearing, confessional type, and he has zealously guarded his family's privacy during his nearly three decades in the Senate. "Personal stuff," as he calls it, makes him squeamish; he'd rather talk about taxes or nuclear energy or almost any piece of pending legislation. With what looked like a nod to himself, however, he continued. "Clare was a very marvelous gifted athlete," he said. "In her best year in high school, she was district champion in tennis; she was a catcher on the baseball team; she was an absolutely outstanding guard on the basketball team." During her freshman year at Wake Forest in North Carolina, however, Clare started to lose her zest, growing "fuzzy" and inordinately indecisive. She would call home frequently for guidance on simple issues, "like what kind of potato to have," Domenici said. "She was all out of whack. Then my wife, Nancy, went down there to help her and ended up bringing Clare back home. That's when things got really out of hand. Her temperament totally changed. She became angry, mean. Throwing things at mirrors. Cussing, swearing. Crying, shrinking into a shell, taking to her bed. And that started two novice parents down the strange path of having to believe something we didn't want to believe. And to really believe it, to acknowledge that Clare was mentally ill, took a long time."

As Domenici exhaled, his assistant tiptoed in to give him a note, and he asked her hopefully, "Meredith, do I have to go to an appropriation meeting?" The assistant shook her head, but Domenici had revealed all he wanted to about Clare for the moment. So he switched gears and talked, in his distinctively folksy and rambling way, about how the happenstance of Clare's illness had redirected his political agenda. If it were not for Clare's struggle with what was finally diagnosed as atypical schizophrenia, it is improbable that Pete Domenici, Mr. Fiscal, would have assumed the unlikely role of champion for the mentally ill. "I don't believe the subject ever would have come up," he acknowledged.

Domenici had made a name for himself as the Republican Party's budget expert. He was a gray, pragmatic fiscal and social conservative who opposed abortion, gun control and same-sex marriage and supported school vouchers, tax cuts and mandatory three-strikes sentencing. He was no bleeding heart, no cause-pleader. But Clare's troubles led Pete and Nancy Domenici into what, 18 years ago, seemed almost like a secret world inhabited by all those whose lives had been touched and ineluctably changed by mental illness. "And once I got into it, I wouldn't have gotten out of it even if somehow Clare would have come out of my mind," Domenici said. "You get into the world of these dread diseases -- you hear stories -- they're terrible from the standpoint of what's happening to these people and what's happening to their families. Society was just ignoring them, denying them resources."

It is strange to think that government works that way, that the fact that a senior senator has a mentally ill daughter can spur governmental action on mental illness. Yet on many issues, politics really is that personal and lawmaking that arbitrary. "You'd be surprised how often legislation is directly informed by our lives," Lynn N. Rivers, a Democratic member of the House from Michigan, says. "In the field of mental health, I think it's possible that nothing at all would have been done by Congress if it weren't for legislators like Domenici who were galvanized by personal experience." Rivers herself has had very direct personal experience; she is a manic-depressive. At a committee hearing this spring, after a couple of witnesses suggested that mental illnesses were not really illnesses, she snapped open her purse and extracted an amber vial -- the pills that keep her healthy -- and shook it like a maraca as if to wake them up.

Over a decade ago, when Domenici embraced the issue, mental illness was not on the national agenda. Americans didn't like to think about it. Even now, although the subject has come out of the shadows and Prozac is in many an American medicine cabinet, Americans remain skeptical and judgmental. Domenici knew that he was growing impassioned about an issue that many of his colleagues would consider marginal, even distasteful, and that he needed colleagues who had been shaken personally, too. He ended up joining forces with a quite liberal Democratic senator, Paul Wellstone, whose older brother had grappled with severe mental illness for many years. Together the "odd couple," in Wellstone's words, nurtured bipartisan alliances with former Senator Alan Simpson, whose niece committed suicide, and Senator Harry Reid, whose father killed himself, and Tipper Gore, who has suffered depression, and Representative Marge Roukema, whose husband is a psychiatrist, and Representative Patrick Kennedy, who has also battled depression, and Senator Edward Kennedy, Patrick's influential father, and Rivers. "There has been a personal, crystallizing experience in each of our lives," Wellstone says. "You almost wish it didn't have to work that way, that all of us would care deeply anyway about people who were vulnerable and not getting the care they need. But this kind of thing happens a lot in politics for fully human reasons."

For 10 long years, Domenici and Wellstone have focused their energies on a law that would force health insurers to treat mental and physical illnesses with full parity. They consider it civil rights legislation, but insurers and employers -- potent lobby groups who view it as a costly and unnecessary new mandate -- have largely succeeded in blocking it. Suddenly this year, however, the two senators feel tantalizingly close to achieving what once seemed a nearly impossible goal. It is odd timing, given the political preoccupation with terrorism, corporate misconduct and Iraq. But perhaps, after "A Beautiful Mind" won its Academy Awards, this was destined to be the year when the mentally ill received their due. Or perhaps it is simply because Pete Domenici has a friend in the White House, and his friend owed him one, and that's the way the chit system known as government works.

When we talked in his office, I asked Domenici if he kept a picture of Clare in the extensive gallery of family photos behind his desk. "Sure," he said. Then he peered over the top of his glasses and rooted around. "Hmmm," he said. "Well. Hmmm. Well. I guess I don't have her here, and I'll have to fix that." He handed me a faded family portrait that looked to be from the 1970's. "That's her right there," he said, pointing to a wan girl with a faraway gaze. "I guess she has a little sad look in that one, doesn't she?" He then ambled over to a display wall adorned with professional artwork from New Mexico. In one corner hung two childlike watercolors -- a vase of flowers and a cluster of sea gulls signed "To Dad, From: Clare." A flicker of a smile crossed Domenici's face. "She's not half bad," the senator said.

The Domenicis live in Washington, down the street from the Ashcrofts and a few blocks from the Senate in a house identifiable by the red chili peppers -- New Mexico's state vegetable -- dangling beside their front door. Clare lives by herself in an apartment in Albuquerque, with two siblings, four aunts, a boyfriend, a case manager, a job coach, a counselor and a doctor on hand to help her cope. Clare does not have hallucinations or delusions, which is why her schizophrenia is labeled atypical. Atypical schizophrenics suffer from losses -- of will and drive, of the ability to experience joy and pleasure, of cognitive functioning. Their affect tends to be flat and their thinking irrational at times.

In Clare's case, this produces debilitating anxiety. Clare's younger sister Paula Domenici, who is a psychologist, described Clare's daily life as racked by "anguish and hell." Nonetheless, like many atypical schizophrenics who respond well to the new low-dose antipsychotic drugs, Clare has found a treatment regime that allows her to be quite functional when she sticks to it. She works; she drives; she sings in her church choir; she plays tennis at an Albuquerque tennis club -- and wins," Paula says. But Clare's condition fluctuates. Recently, she took a leave from her job sorting mail because the stresses of the mail room were getting to her. "Any little thing can rock the boat," Paula says. "She gets very hurt very easily."

The Domenicis have grappled for years with how to balance their daughter's right to, and need for, privacy against the potential public good of talking openly about a senator's daughter's mental illness. "We would ask ourselves, 'Will it do her harm or not?"' Domenici said. And until now, they have always erred on the side of playing it safe, since they are not people who like to talk about themselves anyway. In our first conversation, Domenici squirmed, his eye on his watch. Subsequently, though, he made the decision to surmount his discomfort because he thought it might serve his political ends. Besides, it was his wife who was the really private one.

When I first called Nancy Domenici, who is considered a lay expert on mental health by many in the field, she said: "Gosh, why me? I'm not the most hep person on the subject of mental illness." Eventually, her husband persuaded her to talk. "I didn't want to end up divorced," she joked. Still, because she is either protective or overprotective, she body-blocked the idea of my talking directly to Clare. She said that Clare was simply too "wobbly" right now.

We chatted at her kitchen counter, sipping tea from mugs with rose handles beneath a clock that chirps a different birdsong on every hour. At one point, after the finch cried noon, the phone rang, and Nancy Domenici let the answering machine pick up. "Hi, Mom, this is Clare." Clare was calling in to report to her mother that she would be going to the doctor at 2 p.m. and to her "weigh-in" at 4. (One side effect of her medication has been a weight gain that makes Clare look matronly, and it bothers her, her parents said.) Clare's voice sounded thick around the edges, and it lingered afterward in the air between us.

In a senate coffee shop, with a cup of Starbucks by his side, Domenici doodled on his daily press clippings. "Me/Bush," he wrote. He told me he had always hoped that the stars would line up as they now have, with a president in office whom Pete Domenici had helped elect. "Here's how it worked," Domenici said. "He's kind of my friend. He gets elected. I know there's one thing I really want to do above most other things. I wait a few months after he gets in, and then I request a meeting."

In 1996, Domenici and Wellstone enjoyed their first success after four years of trying to overcome Congress's reluctance to address the problem of inequitable and inadequate insurance coverage for mentally ill Americans. Making a lot of compromises, they won approval for what Domenici now calls "mental illness coverage lite," a first step. The Clinton White House helped, and especially Tipper Gore, who a few years later would disclose her own experience with depression. Newt Gingrich, then the Republican speaker of the House, didn't actively assist but, after a visit from Domenici, he didn't block the legislation either -- which mental-health advocates attribute partly to the fact that Gingrich's mother suffers from bipolar disorder.

Still, the Mental Health Parity Act of 1996 was limited in nature and in effect. It mandated equal annual and lifetime dollar limits for mental and physical benefits; lifetime limits for mental-illness coverage used to be capped at about $125,000, compared with about $1 million -- or sometimes no limit -- for physical disorders. But it allowed employers to comply with the letter rather than the spirit of the law, shifting their costs by raising co-payments and deductibles or lowering limits on hospital days and outpatient visits.

Many states, meanwhile, introduced mental-health parity laws that go further than the federal government's. But even those states possess limited ability to regulate self-financed employer health plans, so Domenici and Wellstone wanted a broad piece of federal legislation that would set the standard. With the 1996 law due to expire by year's end anyway, they are pushing to create the first comprehensive mental-health equitable treatment act.

Mental-health advocates say it will make things infinitely fairer. Without parity, the middle-class parents of a newly psychotic 19-year-old son, say, might discover they have a 30-day lifetime limit on psychiatric hospitalization; that limit might be reached before his illness is even diagnosed, much less treated. They would be left then with three options: go into debt, forgo treatment or turn to the overburdened public sector. If their son had been in a serious car accident, they would face no such predicament.

The Domenici-Wellstone law does make some allowances for the business community's concerns. It does not mandate coverage of mental illnesses; it mandates equal treatment of physical and mental illnesses where such coverage exists. It exempts businesses with less than 50 employees. It doesn't include substance abuse. But insurers and employers are tired of Congress's interference, and they do not see this as a civil rights issue. "There is no right to health care," says E. Neil Trautwein, director of employment policy for the National Association of Manufacturers. "If this issue gets cast that way, it's unfair, and it kind of makes us look like the bad guys. Our members are already providing voluntary coverage."

Many insurers and employers maintain that the parity legislation is misguided, that it will end up backfiring and prompting some providers to drop mental-health coverage entirely. They say that parity for mental-illness coverage, as designed, will drive up health-care costs and that the legislation defines mental disorders so broadly that people with problems like caffeine intoxication or jet lag will abuse the system.

Recently, however, these opponents have lost ground. While Domenici had a couple dozen co-sponsors in 1992, when he first introduced mental-health legislation, he now has 66 senators with him on this. He has been unsuccessful, however, in reaching across the Hill and persuading the House leadership to join him, even though a majority of House members are on record as supportive. And that's why Domenici paid his visit to the Oval Office in July of last year.

Domenici was pleasantly surprised that Bush took the issue seriously enough to ask Andrew Card, his chief of staff, to attend. The senator wasn't certain whether he needed to start at the beginning, to explain that diseases of the brain are as real as diseases of other organs and that they are treatable. "I just plain didn't know where he was on the mental issue," Domenici said. "But I was only a few sentences into it before he stopped me and said, 'On the issue of is this a disease, I've already gone up that mountain."'

Dr. Samuel Keith, chairman of the psychiatry department at the University of New Mexico, participated in a round-table discussion on mental health with Bush in the spring. The president said that he had grown up thinking people with mental problems should just read the Bible and try harder, Keith said. But then, according to Keith, the president told the round-table participants that a close friend in Texas who was profoundly depressed went off and got treatment and returned a transformed man. This opened his eyes, the president said.

The president was also sensitized by the suicide last year of Heinz Prechter, a Michigan businessman, Domenici said, although he was not sure whether Bush had told him this or someone else had. Prechter, who made his fortune after introducing the sunroof in the United States and was a generous donor to the Republican Party, killed himself at the end of a lifelong struggle with bipolar disorder.

During that meeting at the White House last year, Bush told Domenici that 2002 would be a better year. In late April of this year, as promised, Bush flew to New Mexico to stand beside Pete and Nancy Domenici, endorse "full mental health parity" and pledge to get federal legislation passed by year's end. Since then, Bush hasn't put real muscle behind his pledge, and his priorities are clearly elsewhere. Domenici, though, takes it on faith -- a seasoned politician's faith -- that the president will make good on his promise. And the mere fact of Domenici's securing the president's endorsement has forced the law's longtime opponents to think about compromises.

"Our vast preference is no additional mandates, but we don't want to be in an antagonistic position with a longtime friend like Senator Domenici," says Trautwein of the manufacturers' group. He suggested that the manufacturers would consider a narrower version of the law that mandated parity for serious brain-based illnesses like schizophrenia rather than all mental disorders. "We heard the president, and we can count noses. We don't want to see this issue rewound and replayed in the next Congress."

When the Domenicis told Clare that she was going to be part of a magazine article, she didn't have much to say in response. It has always been difficult for Clare to see her situation clearly, her sister Paula says: "Sometimes now she'll say she has a mental illness, which is good. Ten years ago, she wasn't coherent enough in her thinking to realize she was ill."

Ten years ago was a low point. Clare, who was then still living in Washington, would find herself driving around in a fog, unsure of what she was doing or where she was. Eventually, she checked herself into a psychiatric hospital. It was the first and last time that she was hospitalized, her mother says, locked in a closed unit with other mentally ill people, some withdrawn like her and others quite manic or psychotic. During that time, though, Clare was retested, and the Domenicis ended up with a clearer understanding of the chronic nature of her illness and with a better course of medications.

It had been obvious since Clare dropped out of college that her functioning was abnormal, but her family initially thought she was in some kind of extended funk. Maybe it was allergies; it couldn't have been that baseball that struck her in the neck, could it? They didn't know where to turn. "We were kind of in the dark ages in terms of being willing to see a specialist," the senator told me.

Eventually, they found their way to specialists and more specialists. But Clare's symptoms were not clear-cut, making it hard for doctors to diagnose her condition and thus for some in her family to accept that she was in the grip of something that she couldn't snap out of. At a certain point, the senator said, so many years had gone by that "you gotta acknowledge the behavior is not normal and it's probably going to be there for a while."

That acknowledgment, he said, was scary. "When you finally arrive at the conclusion that your child has schizophrenia, you have thoughts of suicide," he said. "They threaten. You really don't know if they're going to follow through. In our case, nothing has happened. But we know friends where something has, and there probably isn't a hell of a lot of difference between the one who does it and the one who doesn't."

Some time after Clare's hospitalization, she moved back to New Mexico. Her family thought that it would be a good idea to get her out of urban D.C. and at something of a distance from her mother, on whom she was extremely dependent. Clare lived for a while in a group home near a state farm in Carlsbad, where she worked as an assistant sports counselor for the mentally retarded residents of the farm.

For a time, Clare was covered by Medicare, since she was collecting Social Security disability insurance payments. Medicare's coverage for mental health is quite skimpy -- only half of treatment costs and no prescription drugs unless you're hospitalized. When Clare started working, she was covered by her employer; the H.M.O. authorizes a limited number of psychiatric visits a year, but Clare's doctor, on her mother's prodding, keeps reauthorizing visits. Nancy Domenici juggles the volumes of paperwork, keeps on top of the bureaucracy and pays out of her pocket for all costs that are not covered. "What if Clare had no parents?" she asks.

Years ago, a neighbor of the Domenicis told them about the National Alliance for the Mentally Ill. The senator and his wife went to a meeting in a church basement and discovered a world of parents dealing with the same issues facing them. "It was a godsend," Nancy Domenici says. And for the alliance too. Pete Domenici heard a lot of depressing stories with bad endings: families going broke, splitting up; mentally ill children ending up on the streets, in jail or dead. Bit by bit, the advocates lured Domenici into involvement, a speech at a convention here, an appropriation there.

It became clear to Domenici that he could do little about one of the most pressing needs, which is an overhaul of the public mental-health system, since that is largely the responsibility of state and local governments. So he focused on what he could get done. He pushed successfully for increased federal appropriations for research into brain diseases, threw his weight behind a private research foundation and backed programs that dealt with housing, public education and the mentally ill who are homeless. Every once in a while, he told me, someone would say to him, "Isn't it good for severe mental illnesses that your daughter got one of them?" He found that distasteful.

Domenici never expected such a protracted battle on the parity legislation, and he is tiring of it. Wellstone is downright antsy, anxious about the president's follow-through. "I haven't seen the evidence yet that the White House will deliver," he said. "I'm certainly more impatient than Pete." But then they are kind of different. Wellstone once called Domenici's office, and an assistant asked him the subject of his call. "I answered: 'Mental health! What the hell else do we agree on?"' Wellstone said.

Unlike Domenici, Wellstone speaks with the cogent passion of a defender of the vulnerable and neglected. He fits more closely the image one might have of a lead advocate for this cause. He traces his political awakening itself to a visit he paid as a 10-year-old to a state mental institution where his college-age brother had been hospitalized after a breakdown. Wellstone's parents had gone deep into debt trying to sustain his brother in a private clinic once their insurance ran out, and the public hospital was a snake pit, he says. "My energy on this issue is fired by tremendous indignation," Wellstone says.

Rivers, similarly, is a natural heroine for the cause. She graduated from high school pregnant, married her high-school sweetheart and started her adult life as a mother bedridden by severe depression. It took her almost a decade after her illness was diagnosed as manic depression to find a mix of medications that would allow her to be symptom-free. Eventually, though, she earned a law degree, became active in local politics and was elected to Congress in 1994 despite acknowledging her illness. ("You betcha!" she said when a caller to a radio show, obviously a plant, asked if she had ever been depressed. "And so have millions of other Americans!") At times, she and her former husband, a boiler engineer, were spending half their take-home pay on her barely insured treatment, so she takes the parity issue very personally. The only possible explanation for employers' and insurers' reluctance to cover mental illnesses on a par with physical illnesses, she says, is "ignorance or greed."

Last year, when Rivers learned that she would have to face Representative John Dingell in a Democratic primary after her district was redrawn, she was beset by anxiety. But not for political reasons. "The one thing that frightened me was not running against the dean of the House, not all the money he was going to have, but this terrible fear that if I lost, I would lose my health insurance." Rivers is covered under a federal employees' plan that guarantees full parity coverage. "I am not smug enough to believe that I am not at risk of relapse, and my terror is getting sick again without having appropriate insurance," she said in July. Dingell did indeed beat Rivers in the August primary, leaving her to face these concerns.

In contrast to Wellstone and Rivers, Domenici can seem uninspired, even inarticulate, in making his case. He uses euphemisms, talking about mentally ill people as being "under the shell" or "coming out from the shell" after treatment. He asks: "Is a severe schizophrenic 19-year-old who's been catatonic -- they finally got him out of it but now he's gained weight and weighs 300 pounds because that's the side effect -- is that less bad than someone with cancer?" But advocates for the mentally ill believe that Domenici's folksy awkwardness on the subject of mental illness can be quite effective, precisely because the subject makes many Americans uncomfortable. And it is, they suggest, also something of an act. Domenici's expertise is probably unparalleled on the Hill, they say, and more important, it is his political know-how, the way he bargains behind closed doors, that counts.

Andrew Sperling, legislative director for the National Alliance for the Mentally Ill, says that Domenici has played a singular role precisely because he is such an unlikely advocate. "If the parity legislation had come along as a Kennedy-Wellstone initiative, it would never have been taken seriously in the Senate. Democrats come up with mandates on health insurance every day. But when a senior Republican senator with a fairly conservative voting record comes forward and says that in this instance the federal government has a responsibility to set a standard on the marketplace -- it has the flavor of a Nixon in China."

As year's end approaches, Domenici knows that Clare's law, like Clare herself, needs to be watched and tended if it is not to be overlooked or derailed. He hesitantly confided that he expected Clare to marry in the near future, and it is clear that he is ready for some kind of ceremony -- the Rose Garden, maybe -- on the legislative front too. "We've been doing this for a long time," he said, "and I am older than some people think."
 

bullet

horizontal rule

 

bullet California, US - LAURA'S LAW SIGNED BY GOVERNOR DAVIS
NEW LAW REFORMS TREATMENT OF SERIOUSLY MENTALLY ILL

GOVERNOR DAVIS SIGNS LAURA'S LAW 9/28/2002

'Laura's Law' Will Allow Court-Ordered Treatment Of Mentally Ill.

By Dan Morain And Carl Ingram, Times Staff Writers
SACRAMENTO -- Gov. Gray Davis signed legislation Saturday permitting
authorities to treat severely mentally ill people against their will if
judges conclude that they cannot care for themselves and are likely to
become dangerous.

The legislation represents a significant amendment to a state law that
protects the civil rights of mentally ill people, the 30-year-old
Lanterman-Petris-Short Act. The act helped lead to the emptying of
state hospitals, which once housed more than 30,000 people but now care for
4,000. All but about 800 of those remaining patients have committed
crimes and were sent to institutions by courts.

The legislation, Assembly Bill 1421, establishes a hearing process in
which judges will determine whether the person has a history of failing
to comply with treatment and has, within four years, exhibited "serious
violent" behavior against others, or tried to hurt himself or herself.
The individual could be represented by a public defender or a private
lawyer.

Davis said he expects the measure to help reduce homelessness,
hospitalization and involvement in the criminal justice system.

"This is a critical step in helping the seriously mentally ill, as well
as their families," Davis said in a statement, predicting that the bill
would "help end the cycle of hospitalization, quitting treatment and
relapse."

Davis' decision to sign the bill marked a victory for Assemblywoman
Helen Thomson (D-Davis) in her final year in the lower house. Thomson
tried for five years to win approval of the measure, which was backed
by law enforcement and many family members of the mentally ill. Liberals
in the Legislature, siding with some patients' rights activists, had
blocked its passage until this year.

Thomson called the final version of the bill "Laura's law," named for
Laura Wilcox, a 19-year-old woman who worked at a Nevada County mental
health facility and was killed by a man whose mental illness had gone
untreated. It is similar to a New York law adopted in 1999 after a
mentally ill man pushed 32-year-old Kendra Webdale into the path of a
subway train.

As part of the compromise, counties will have the option of
participating, and would bear the costs. People would be treated in
expanded outpatient programs considered the "least restrictive"
necessary to achieve recovery.

Under current law, people generally can be detained for 72 hours. In
extreme cases, they can be held for six months. The law provides
parents and other family members of adults who are mentally ill little or no
opportunity to intervene on the individual's behalf. Thomson's bill
will allow family members to testify at hearings.

"I don't think it will have any impact on the population in state
hospitals," said Stephen W. Mayberg, director of the state Department
of Mental Health. "Our goal is to treat people not in institutional
settings."
 

horizontal rule

Marketletter, September 2, 2002

UK law and upcoming injectable drugs to treat schizophrenia and bipolar disorder

Manufacturers of antipsychotic drugs are set to launch longer-lasting injectable products which will help combat the problem of poor patient compliance in the treatment of schizophrenia and bipolar disorder, says new research from Datamonitor.

These drugs, which include Novartis' Zomaril (iloperidone) and Bristol-Myers Squibb's Abilitat (aripiprazole), may have an important role if the UK government's bill to force treatment of community patents is passed, because they can ensure that the drugs are taken once every two weeks or possibly monthly, it adds.

However, the study warns that antipsychotic injections are likely to have mixed success. While they are particularly useful when treating patients in the acute phase of schizophrenia, the length of efficacy may be subject to controversy, as administering long-lasting medication decreases the ability of the patient to influence their own treatment, which is considered a patient right in most circumstances. In June 2002, the UK government proposed several changes in the treatment of the mentally ill, one of which will force patients in the community to undergo treatment without the need to be sectioned. In this situation, a long-acting antipsychotic would be particularly useful, says Datamonitor, because patients in the community could visit a health care professional every two weeks, or possibly every month, and compliance could be ensured.

A major issue in treating patients who suffer from spells of psychosis is that, once their health improves, they are allowed into the community. However, their chances of staying healthy are reduced because they are not obliged to continue taking medication, says the report, which adds that the introduction of longer-lasting drugs should increase patient compliance greatly and, as such, help to reduce this risk.

Nevertheless, Datamonitor believes the future treatment of these disorders will reside in receptor-specific compounds that can be combined into a tailor-made polytherapy to suit an individual's needs, with movement towards this type of therapy already being seen in early-stage programs.

horizontal rule

bulletNew Book: "Beyond Crazy" by Julia Nunes and Scott
Simmie, published by McClelland & Stewart. Sept 2002
ISBN 0-7710-8068-9 $34.99 Canadian dollars

********************************************
Toronto Star October 1, 2002
 

No looking back

By Julia Nunes and Scott Simmie

With the help of her mom, an indomitable young woman tames a terror from the past
 

bulletThis is a tale of two generations. It's a sad story that leads to a much happier one. And it begins in 1980, in the small Northern Ontario city of Sault Ste. Marie. Terry-Lee Marttinen is 16 years old, dating a young man named John (a pseudonym) when she discovers she's pregnant. Something equally unexpected is happening to John. His behaviour has become increasingly bizarre: he's smoking marijuana, dabbling in the occult. Terry-Lee is scared; she stops seeing him.
Over the next four years, John winds up in and out of hospital. Much later - too late - doctors determine he's been suffering from schizophrenia.
One summer day in 1984, when his daughter Tara is 3, John succeeds after several attempts at suicide. He is 22 years old.
About a decade later, another young life is entering those delicate teen years. And Tara Marttinen is herself beginning to feel different. To the outside world, nothing is seriously wrong. After all, what teenager doesn't stay up late or let their grades slip slightly?
Then one day as she sits at her desk in class, he hears, for the first time ever, a voice in her head. "It was out of the blue. I heard: 'Take off your shoes and sit under your chair.' Really loud, sort of screaming in my ear."
For the next several months she carries on with her classes, her meals with her mom, and nights out with friends as if nothing's wrong. She shares her secret with no one. But late at night, she lies awake for hours, lost in a jumble of racing thoughts.
At 16, partway through Grade 11, Tara finally "spills the beans" to her mother. And immediately, Terry-Lee thinks of schizophrenia. "When she told me she was hearing voices, I knew instantly. Just instantly. My little back went up and I was instantly fearful."
We meet Terry-Lee and Tara at a cafe in downtown Toronto. It's the start of a mini-vacation they've been planning for weeks. Together, they're visiting relatives, taking in the sights, and "shopping, shopping, shopping."
Mother and daughter have matching blond hair, blue-grey eyes, and friendly smiles. When one speaks, the other nods; often, they finish each other's sentences.
"We've been together a long time," Terry-Lee says proudly. "Just me and her. Being a young single mom, I think Tara and I have been really close."
Tara nods in agreement. "I actually like hanging out with my mom. ... It's relaxing to be around someone who understands you." Tara is wafer-thin with finely carved cheekbones, alabaster skin, and a small silver hoop through her left eyebrow just above her funky black eyeglasses.
"We're very lucky," she says. "I'm very lucky."
Tara and Terry-Lee want to share the story of what's made them lucky. Of how they got from there to here. There was Tara sitting alone in her room, writing page after page of anguished poetry. Here is Tara finishing high school with honours, Terry-Lee preparing to send her off to university. "I'm relieved," Terry-Lee says. "I was so scared. And now I know it's okay. I have a safe feeling inside."
The one thing Terry-Lee knew when she found out about the voices was that Tara needed help away from home. "I just made the assumption that the care wouldn't be any good in the Soo because of Tara's father's care."
With a phone call to a distant uncle who worked in the mental health field, Terry-Lee arranged an appointment at a clinic in London, Ont., seven hours away by bus. They didn't know it at the time, but what they'd stumbled into was a leading-edge treatment facility for first-episode psychosis. Dr. Ashok Malla runs the Prevention and Early Intervention Program for Psychoses, or PEPP. Soon they were sitting in his office as he led them through a clinical assessment.
Straight away, Dr. Malla recognized the early signs of psychosis. Before he'd even diagnosed Tara with schizophrenia, he prescribed a low dose of an atypical antipsychotic medication. "If we see symptoms, if they've been there for more than a week, we treat them," Dr. Malla says.
Tara was also given a brain scan in a magnetic resonance imaging machine. "That was the scariest thing," she says. "But I just had this feeling: After this it's going to be better."
Tara was never hospitalized, never needed to be. Instead, she and Terry-Lee returned home and went on with their lives.
Slowly, the voices faded away. But other challenges remained. Schoolwork was harder than it had been, and even hanging out with friends could be exhausting. "I missed, on average, one day a week out of school. ... I'd be wiped out. There was too much going on."
Tara was tackling head-on the kind of life changes none of her friends were interested in making. Late-night partying gave way to quieter activities: jewellery-making, journal-writing, embroidery. The junk food was tossed - no more Cheez Whiz sandwiches - and replaced with a high-protein, low-sugar diet bolstered with vitamins. (Terry-Lee had done the research on
the Internet.)
Twice a year, mother and daughter made the long trip to London for consultations with Dr. Malla.
If all this sounds simple, it hasn't been, as Tara wrote in a PEPP newsletter: "I can't for even one day (diverge) from my regimen of taking my vitamins, going through my day free of over-stimulation, then taking my medication, and finally, going to bed at a decent hour. If one of these elements were missing it would have drastic effects on my performance the next day."
The payoff, however, has been huge. In five years, Tara has never had a relapse. "I know when something's wrong," she says, "and when I should rest."
Dr. Malla is thrilled with Tara's progress. "She has a vision of her life," he says, "of what she wants to do."
What Tara wanted to do, after high school, was go to university. In Sault Ste. Marie, that meant leaving home. "We're trying to be realistic," Terry-Lee says. "Do the homework, cover the bases, and then leap off the cliff."
The homework included choosing university in London, where Dr. Malla is. Tara worked for a year after high school to save money. She applied for student loans, and won scholarships to help pay for tuition and books. And she decided against a room in residence - "too chaotic, too much going on," says Tara.
Today, the results of all that can be found on a secluded street in a clean and cozy apartment in an old house. This is Tara's new home, the start of her new life. "I like living on my own right now," she says. "It's very comfortable. It's my own space."
Tara is pacing herself carefully. Taking three classes (English literature, calculus, psychology) instead of a full course load of five. Keeping the usual first-year socializing to a minimum. "I'm a loner anyway," she says with a self-deprecating laugh.
In her mind's eye, she carries a picture of the future. A four-year honours degree in psychology completed over five years, including summer classes and a full course load in the final year. After that, a career counselling teens with mental health issues. Even further down the road, she foresees marriage and kids, and perhaps a chance to be medication-free. "If for some reason my brain's sort-of levelled out again ... I don't want to be on meds and having kids."
But for now, she's focused on school. She says she's not even looking for a boyfriend. "I don't want to be with a person who doesn't respect my illness and understand the importance of it," she says firmly. "It's a big part of my life. I don't want it to be, but it is. It's something I have to deal
with, and they would, too, as a result of being with me. ... And I don't think right now anybody's prepared for that."
Back at the cafe table, Terry-Lee shakes her head, amazed. "She's wise. She freaks me out. But I understand why she's wise. Tara's spent more time thinking about the meaning of life than most people do in a lifetime."
Tara, slightly embarrassed, allows that she has "grown up fast." But she finishes her thought in a way that reminds us she isn't too grown-up just yet. "It's like you're sixteen," she says, "and suddenly feel thirty, you know?"
Because the comment draws laughter from the rest of us at the table, Tara - ever considerate - adds: "Forty, eighty, whatever. More like eighty." Then, discreetly, she smiles.

Tara Marttinen is now in her second year of university. This is a condensed excerpt from the book "Beyond Crazy"
by Julia Nunes and Scott Simmie,
McClelland & Stewart. ISBN 0-7710-8068-9

http://www.mcclelland.com/catalog/display.pperl?isbn=0771080689

bullet 
bullet

horizontal rule

bullet Windsor Star

October 10, 2002

Path of doom starts with homelessness; Squalor 'breaks your heart'

Windsor Star

BYLINE: Veronique Mandal Star Health-Science Reporter

Angela adjusts the grocery bag on her arm, unlocks the door to her schizophrenic son's bachelor apartment and enters a rat-infested hole. She cries. "We've complained to the landlord a hundred times but nothing gets done. It breaks our hearts and we want to take him home but he wants to make it on his own," says Angela, a Windsor mom. "He's not good at standing up for himself and his paranoia works against him because the landlord sees it and treats him like a dog. It's almost impossible for people like him to get a decent place to live that they can afford."

Angela's story is repeated thousands of times across Canada, illustrating the plight of the 25 to 60 per cent of the homeless who have a serious mental illness.

Their homelessness sets up a vicious cycle of psychotic events leading to hospitalization or incarceration, discharge to the streets and relapse.

"Without a proper home where they're stable, without someone to keep an eye on them and an opportunity to have self-worth, they're lost," said Wendy Forrest, a mental health court case manager in Toronto. "There are times when I visit a client and walk away in tears. It breaks your heart to see where many of them end up."

Canada's largest city has 62,000 on its subsidized housing waiting list, many of whom are mentally ill.

"There aren't even enough of the rat holes around let alone something that's fit for human habitation and the people most often stuck on the streets are the most seriously mentally ill," Forrest said.

The mentally ill, especially those with paranoid schizophrenia, often prefer the streets to sleeping in a room with a dozen other people and consider the street safer, she said.

In Windsor, where up to 50 mentally ill people per night are looking for a bed, Laura Bedard of the Schizophrenia Society of Ontario said many clients live in rest homes. They range from excellent to disgusting. About 11 private lodging homes house close to 400 residents.

"Some have bathrooms with no doors, some have co-ed bathrooms, substandard food and sleep two to six in a room," said Bedard. "We hear awful stories from people."

A major problem for the mentally ill is the way the government pays their disability pensions. If they are in a hospital or in jail waiting for a psychiatric assessment longer than 30 days, their pensions are cut off and they lose their room or apartment. They come out of hospital or jail and are forced back on the street.

bullet

horizontal rule

Research yields better meds; Reducing side-effects, psychotic episodes the goal

Windsor Star

BYLINE: Veronique Mandal Star Health-Science Reporter

Scientists attempting to design brain-shielding drugs for the mentally ill are inching closer to curing schizophrenia.

"It could be tomorrow but it could also be 20 years from now," said Dr. Barry Jones, a researcher with the pharmacutical firm Eli Lilly in Toronto.

Understanding the path to a cure begins with understanding how drugs work on the schizophrenic brain. Anti-psychotics block the overproduction of the chemical dopamine, particularly in the limbic system, an old part of the brain which causes psychotic symptoms -- voices and paranoid delusions. Newer drugs also treat more emotional symptoms such as withdrawal and cognitive dysfunction. And they reduce the debilitating motor side-effects which can produce Parkinson-like symptoms such as the shakes.

The drugs also block another receptor for a chemical called seratonin which makes the frontal cortex of the brain more active. In schizophrenia the frontal cortex is slow and affects emotion and cognitive functioning.

The frontal cortex is the most highly developed part of the brain. It develops last and is not complete until the mid-20s, when schizophrenia typically develops.

"This is why schizophrenia could develop in younger children but is not evident until the late teens," said Jones. "It gives us our humanity, abstract thought, motivation and decision-making. It's silent but dramatic. Psychosis is the noisy part."

Because repeated psychotic events destroy grey matter, Jones said it's important to develop new drugs to prevent it. A chemical in Lilly's drug olanzapine appears to do that in a small way.

"The aim is a brand new drug to protect the brain from psychosis," he said

Once the genetics of schizophrenia are better understood, Jones expects the next stage to be a cure.

Traditionally, doctors have had difficulty keeping schizophrenics on their meds. Anti-psychotic drugs cause everything from drooling and lethargy to gross weight gain and possible links to heart disease and diabetes.

Many schizophrenics get fed up having to take a dozen or more pills a day.

McGill University psychiatrist Dr. Howard Margolese, a leading researcher in the field, said while it's preferable to have patients on fewer medications, it often takes several to deal with the symptoms.

"All anti-psychotics are effective against the positive symptoms of schizophrenia but we have to use an anti-depressant if the person is depressed and anti-anxiety medication if they're agitated and sometimes they need a drug to counteract the side-effects," said Margolese.

A study in the British Medical Journal said the average annual cost of keeping a person on anti-psychotics in Canada is $4,500. The average cost to hospitalize that person is $39,000.

Home About Links Search Advocacy Editorial Experiences News Newsletters People Research Recovery Santa Cruz Site Map Guest Book

Opinions expressed in this web site do not necessarily reflect the views of NAMI Santa Cruz County, NAMI California or any affiliated organizations.  We attempt to present a balanced perspective on issues by presenting multiple viewpoints.

Copyright 2005 National Alliance for the Mentally Ill Santa Cruz County, All Rights Reserved.

FAIR USE NOTICE: This may contain copyrighted (©) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available to advance understanding of ecological, political, human rights, economic, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml  If you wish to use copyrighted material for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner.